← Back to Search

Other

A Study of LY3457263 in Obese Participants

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 up to 43 days postdose

Summary

This trial is testing a new drug called LY3457263 together with tirzepatide to see if they are safe and well-tolerated in overweight or obese people. The study will also measure how much of LY3457263 gets into the bloodstream and how long it stays in the body. The trial will last a few months.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 up to 43 days postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 up to 43 days postdose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Therapeutic procedure
Secondary study objectives
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3457263

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3457263 + TirzepatideExperimental Treatment2 Interventions
LY3457263 administered subcutaneously (SC) in combination with tirzepatide given SC.
Group II: Placebo + TirzepatidePlacebo Group2 Interventions
Placebo administered SC in combination with tirzepatide given SC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3457263
2022
Completed Phase 1
~200
Tirzepatide
2019
Completed Phase 3
~7520

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,466,346 Total Patients Enrolled
69 Trials studying Obesity
47,049 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,391 Previous Clinical Trials
428,803 Total Patients Enrolled
52 Trials studying Obesity
25,854 Patients Enrolled for Obesity
~12 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top